Breaking Finance News

Athenahealth Inc (NDAQ:ATHN) has been downgraded from Buy to Neutral in a statement by Dougherty & Company earlier today.

Showing a price of $137.45, Athenahealth Inc (NDAQ:ATHN) traded 0.87% higher on the day. The last closing price is up 11.85% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. ATHN has recorded a 50-day average of $142.63 and a two hundred day average of $125.50. Trade Volume was down over the average, with 245,801 shares of ATHN changing hands under the typical 683,545

Dougherty & Company has downgraded Athenahealth Inc (NDAQ:ATHN) from Buy to Neutral in a statement released on 07/07/2017.

Recent Performance Chart

Athenahealth Inc (NDAQ:ATHN)

Athenahealth Inc has price-earnings ratio of 178.13 with a one year low of $90.11 and a 52 week high of $158.66 and has a market cap of $0.

General Information About Athenahealth Inc (NDAQ:ATHN)

athenahealth, Inc. provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet. The Company has a range of network-enabled services to support healthcare providers across the continuum of care. The Company offers various combinations of its services to its clients, including athenaOne and athenaOne for Hospitals and Health Systems, depending on whether they are medical groups and practices or hospitals and larger health systems. As of December 31, 2016, the Company connected care across a national network of approximately 88,000 providers and approximately 86 million patients. Its suite of network-enabled services includes athenaCollector, athenaClinicals, athenaCommunicator, athenaCoordinator, Population Health and Epocrates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.